Compare Futu Holdings Ltd (FUTU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Futu Holdings Ltd vs Merck & Co., Inc. — how do they compare? Futu Holdings Ltd trades at $111.21 (market cap $15.25B), while Merck & Co., Inc. trades at $142.58 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 23× Futu Holdings Ltd's market cap, and Merck & Co., Inc. is trading nearer its 52-week high, Futu Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Futu Holdings Ltd for 34 Days and Merck & Co., Inc. for 98 Days on average.
| FUTU | MRK | |
|---|---|---|
Market Cap | $15.25B | $351.28B |
Volume | 812,567 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $199.04 | $156.43 |
52-Week Low | $89.76 | $82.49 |
Typical Hold Time | 34 Days | 98 Days |
Enterprise Value | $15.59B | $398.04B |
Dividend Yield | 2.39% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Futu Holdings (FUTU) trades at $109.68, down 3.12% today, amid a bearish technical signal but strong fundamentals. Revenue grew to $22.85B in 2025 with a net income margin of 49.62%, while valuation ratios like a P/E of 10.95 suggest potential undervaluation. Recent news includes Moomoo's partnership with X and a class action lawsuit deadline, adding mixed sentiment.
The outlook is cautiously optimistic due to robust earnings growth and analyst upside targets near 33%, but risks from legal issues and competitive pressures warrant monitoring. Investors may find value if the company executes on overseas expansion, though volatility from technical bearishness persists.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Futu Holdings Ltd
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services.
Read more on FUTU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
